A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI188 in Advanced Malignancies

NCT03717103 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignancies

Interventions

DRUG: IBI188

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.